These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18663761)

  • 1. Group sequential and adaptive designs - a review of basic concepts and points of discussion.
    Vandemeulebroecke M
    Biom J; 2008 Aug; 50(4):541-57. PubMed ID: 18663761
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of draft FDA adaptive design guidance.
    Cook T; DeMets DL
    J Biopharm Stat; 2010 Nov; 20(6):1132-42. PubMed ID: 21058109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On flexibility of adaptive designs and criteria for choosing a good one--a discussion of FDA draft guidance.
    Cheng B; Chow SC
    J Biopharm Stat; 2010 Nov; 20(6):1171-7. PubMed ID: 21058113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On efficient two-stage adaptive designs for clinical trials with sample size adjustment.
    Liu Q; Li G; Anderson KM; Lim P
    J Biopharm Stat; 2012; 22(4):617-40. PubMed ID: 22651105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Issues in the use of adaptive clinical trial designs.
    Emerson SS
    Stat Med; 2006 Oct; 25(19):3270-96; discussion 3302-4, 3320-5, 3326-47. PubMed ID: 16906553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Adaptive designs for clinical trial].
    Li W; He SJ; Wang Y; Cheng XR; Jia X
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Jun; 28(6):605-7. PubMed ID: 17939395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the FDA guidance on adaptive designs: historical, legal, and statistical perspectives.
    Liu Q; Chi GY
    J Biopharm Stat; 2010 Nov; 20(6):1178-219. PubMed ID: 21058114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of adaptive allocation rules for group-sequential binary response clinical trials.
    Morgan CC; Stephen Coad D
    Stat Med; 2007 Apr; 26(9):1937-54. PubMed ID: 16981177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptive designs in clinical drug development: opportunities, challenges, and scope reflections following PhRMA's November 2006 workshop.
    Krams M; Burman CF; Dragalin V; Gaydos B; Grieve AP; Pinheiro J; Maurer W; Gallo P
    J Biopharm Stat; 2007; 17(6):957-64. PubMed ID: 18027207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive designs with correlated test statistics.
    Götte H; Hommel G; Faldum A
    Stat Med; 2009 May; 28(10):1429-44. PubMed ID: 19226563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adaptive, group sequential and decision theoretic approaches to sample size determination.
    Mehta CR; Patel NR
    Stat Med; 2006 Oct; 25(19):3250-69; discussion 3297-301, 3302-4, 3313-4, 3326-47. PubMed ID: 16927402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction to discussion papers on draft FDA guidance on adaptive designs.
    Chang M
    J Biopharm Stat; 2010 Nov; 20(6):1113-4. PubMed ID: 21058106
    [No Abstract]   [Full Text] [Related]  

  • 13. Note on special technical issue on adaptive designs for clinical trials.
    Liu Q; Chang M
    J Biopharm Stat; 2012; 22(4):615-6. PubMed ID: 22651104
    [No Abstract]   [Full Text] [Related]  

  • 14. A note on special articles on adaptive clinical trial designs.
    Chow SC
    J Biopharm Stat; 2010 Nov; 20(6):1088-9. PubMed ID: 21058103
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficient group sequential designs when there are several effect sizes under consideration.
    Jennison C; Turnbull BW
    Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adaptive designs for confirmatory clinical trials.
    Bretz F; Koenig F; Brannath W; Glimm E; Posch M
    Stat Med; 2009 Apr; 28(8):1181-217. PubMed ID: 19206095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive seamless designs: selection and prospective testing of hypotheses.
    Jennison C; Turnbull BW
    J Biopharm Stat; 2007; 17(6):1135-61. PubMed ID: 18027222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA perspective on trials with interim efficacy evaluations.
    Temple R
    Stat Med; 2006 Oct; 25(19):3245-9; discussion 3326-47. PubMed ID: 16847824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal spending functions for asymmetric group sequential designs.
    Anderson KM
    Biom J; 2007 Jun; 49(3):337-45. PubMed ID: 17623339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Editorial: Adaptive designs: appealing in development of therapeutics, and where do controversies lie?
    Wang SJ
    J Biopharm Stat; 2010 Nov; 20(6):1083-7. PubMed ID: 21058102
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.